Yoga to Improve Disparities in Cancer Survivorship (NCT07165600) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Yoga to Improve Disparities in Cancer Survivorship
United States8 participantsStarted 2025-09-24
Plain-language summary
This clinical trial tests the impact of a racially concordant trainer led yoga program on quality of life and symptom burden in Black and/or African American cancer survivors. Black individuals in the United States are more affected by cancer, despite modern advances. Cancer treatments can impact physical and mental health and overall quality of life and Black individuals report worse physical function and quality of life and less access to culturally appropriate support services. Yoga has been shown to have a positive impact on cancer and cancer treatment related symptoms and quality of life, however, a one size fits all approach has not been shown to be effective in diverse populations. A trainer that shares the same racial or ethnic background as the participant (racially concordant) may have a positive impact on communication, trust, and may improve accessibility and participation. Participating in a yoga program led by a racially concordant trainer may improve quality of life and symptom burden in Black and/or African American cancer survivors.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>=18 years.
✓. Able to understand study procedures and to comply with them for the entire length of the study.
✓. Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
✓. Diagnosed with any malignancy and/or received any cancer directed therapy within 5 years of enrollment.
✓. Be able to speak, read and write in English.
✓. Self-identify as Black or African American race.
✓. Reside in California.
Exclusion criteria
✕. Contraindication to any study-related procedure or assessment.
✕. Planned major surgery during the study period.
✕. Any major injuries that limit physical activity.
What they're measuring
1
Overall completion rate
Timeframe: Up to 8 weeks
2
Median score on the Feasibility of Intervention Measure (FIM)
Timeframe: Up to 8 weeks
3
Median score on the Acceptability of Intervention Measure (AIM)
Timeframe: Up to 8 weeks
4
Median score on the Intervention Appropriateness Measure (IAM)
. Active or radiographic evidence of cancer requiring treatment during the study period. Adjuvant therapy is allowed (including hormonal, immuno-, or targeted therapy). Ongoing treatment such as hormone or maintenance therapies including HER2 directed, or immunotherapy are only allowed if patient has no evidence of disease on most recent imaging.